trial

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCTId NCT04226898
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 68 (estimated)
Sponsored by Sheppard Pratt Health System
Primary completion 2027-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
68 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-02-21
Primary completion
2027-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Synbiotic SupplementInert Compound

Sponsors

Sheppard Pratt Health SystemLead Sponsor

Investigators

1
Faith B Dickerson, PhD, MPHPrincipal Investigator

Sites

1 total
Batlimore, United States

Linked catalysts

1
Synbiotic Compound to Reduce Symptoms of Schizophrenia — primary completion2027-03

Facts & assertions

4 sourced
Enrollment
68
Phase
PHASE2
Primary Completion Date
2027-03
Status
RECRUITING
relationships
The graph out of here
drug
Synbiotic Supplement
drug
Inert Compound
drug
lead_sponsor
Sheppard Pratt Health System
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Faith B Dickerson, PhD, MPH
person